Abstract
The selective estrogen receptor modulator raloxifene significantly improved memory and attention/processing speed relative to placebo in a 13‐week crossover trial that included both men and women with schizophrenia. Raloxifene did not result in a reduction in symptom severity, however.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
